Literature DB >> 20570587

Interethnic differences in ADMA concentrations and negative association with nitric oxide formation in preeclampsia.

Valeria C Sandrim1, Ana C T Palei, Ingrid F Metzger, Ricardo C Cavalli, Geraldo Duarte, Jose E Tanus-Santos.   

Abstract

BACKGROUND: Recent studies have suggested that impaired nitric oxide (NO) formation in preeclampsia may result from increased concentrations of an endogenous NO synthase inhibitor, the asymmetric dimethylarginine (ADMA). However, no previous study has examined whether a negative association exists between ADMA and nitrite concentrations in preeclampsia. Moreover, no previous study has compared ADMA and nitrite levels in black and white preeclamptic pregnant women.
METHODS: We measured plasma nitrite concentrations using an ozone-based chemiluminescence assay, and plasma ADMA levels using enzyme immunoassays in 94 pregnant (47 healthy pregnant: 16 blacks and 31 whites; and 47 preeclamptic: 14 blacks and 33 whites).
RESULTS: We found higher ADMA (2.199 + or -0.016 micromol/l vs. 2.112 + or - 0.012 micromol/l; P<0.0001) and lower plasma nitrite levels (102 + or - 7.1 nmol/l vs. 214.8 + or - 26.1 nmol/l; P<0.0001) in preeclamptic compared with healthy pregnant women. Black pregnant had higher ADMA levels than white pregnant women (P<0.05), both in preeclamptic (2.239 + or - 0.020 micromol/l vs. 2.144 + or - 0.019 micromol/l) and in healthy pregnant (2.172 + or - 0.025 micromol/l vs. 2.077 + or - 0.018 micromol/l). Conversely, we found no significant effects of ethnicity on the plasma nitrite levels, both in healthy pregnant and in preeclamptic women (P>0.05). We found a significant negative correlation (P<0.05) between these markers (r=-0.28; P<0.05).
CONCLUSIONS: Our findings show higher ADMA and lower nitrite levels in preeclamptic compared with healthy pregnant, and the concentrations of these biomarkers are inversely associated. While ethnicity affected ADMA concentrations, no such effect was found with respect to nitrite levels. These results may have important implications for studies on NO biology and therapeutic approaches of preeclampsia. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570587     DOI: 10.1016/j.cca.2010.05.039

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

Review 1.  Pathophysiology and Current Clinical Management of Preeclampsia.

Authors:  Lorena M Amaral; Kedra Wallace; Michelle Owens; Babbette LaMarca
Journal:  Curr Hypertens Rep       Date:  2017-08       Impact factor: 5.369

Review 2.  Preeclampsia: long-term consequences for vascular health.

Authors:  Lorena M Amaral; Mark W Cunningham; Denise C Cornelius; Babbette LaMarca
Journal:  Vasc Health Risk Manag       Date:  2015-07-15

Review 3.  Endothelial dysfunction and preeclampsia: role of oxidative stress.

Authors:  Lissette C Sánchez-Aranguren; Carlos E Prada; Carlos E Riaño-Medina; Marcos Lopez
Journal:  Front Physiol       Date:  2014-10-10       Impact factor: 4.566

4.  Circulating Total Cell-Free DNA Levels Are Increased in Hypertensive Disorders of Pregnancy and Associated with Prohypertensive Factors and Adverse Clinical Outcomes.

Authors:  Lorena M Amaral; Valeria C Sandrim; Matthew E Kutcher; Frank T Spradley; Ricardo C Cavalli; Jose E Tanus-Santos; Ana C Palei
Journal:  Int J Mol Sci       Date:  2021-01-08       Impact factor: 6.208

5.  Evaluation of the predictive values of elevated serum L-homoarginine and dimethylarginines in preeclampsia.

Authors:  Xiangmei Yuan; Leiming Cai; Fengmei Hu; Li Xie; Xiong Chen; Jingjing Wu; Qian Li
Journal:  Amino Acids       Date:  2022-06-26       Impact factor: 3.789

6.  Association of endothelial nitric oxide synthase gene variants with preeclampsia.

Authors:  Ghazala Shaheen; Sarwat Jahan; Nousheen Bibi; Asmat Ullah; Rani Faryal; Ali Almajwal; Tayyaba Afsar; Dara Al-Disi; Mahmoud Abulmeaty; Abdulaziz Abdullah Al Khuraif; Mohammed Arshad; Suhail Razak
Journal:  Reprod Health       Date:  2021-07-28       Impact factor: 3.223

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.